<DOC>
	<DOCNO>NCT00471510</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy three dose topical NEOSH101 apply once-daily ( qd ) 16 week men thin hair top center scalp ( Norwood/Hamilton grade III-IV androgenetic alopecia ) . Four equally size treatment group ( 35 men ) receive either NEOSH101 0.5 % , NEOSH101 1.0 % , NEOSH101 2.0 % placebo . A 12-week observation period follow treatment period .</brief_summary>
	<brief_title>Dose-Ranging Efficacy Study Topical NEOSH101 Treat Male Pattern Hair Loss</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>Men , age 18 49 year , general good health Norwood/Hamilton grade III IV androgenetic alopecia , thin hair vertex area Concomitant dermatologic medical condition ( ) may interfere investigator 's ability evaluate subject 's response study drug Treatment systemic locally acting medication may interfere study objective , minoxidil treatment 6 month prior study day 1 , finasteride treatment 12 month prior study day 1 , treatment investigational hair growth product 6 month prior study day 1</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>androgenetic alopecia</keyword>
	<keyword>male pattern hair loss</keyword>
	<keyword>male pattern baldness</keyword>
	<keyword>androgenetic alopecia male pattern hair loss</keyword>
</DOC>